NPPA Cuts Prices of 543 Cancer Drugs: 73% Reduced, MRP Cap of 30% Trade Margin Effective from 9 November
How much it matters for each exam
- UPSC7/10
- SSC7/10
1At a glance
The National Pharmaceutical Pricing Authority (NPPA) has revised the Maximum Retail Prices (MRP) for 543 cancer drug brands/packs. 73% of these (397 drugs) have seen price reductions, with 217 slashed by over 50%. This follows a government order capping the trade margin for 137 anti-cancer drugs at 30% of MRP. The new prices come into effect from 9 November 2026.
Massive Price Cuts
NPPA has reduced prices for 73% of 543 cancer drugs, with over 200 seeing cuts greater than 50%.
Margin Regulation
Prices revised under a government order capping trade margins at 30% of MRP for 137 anti-cancer drugs.
Patented Drugs Unchanged
Prices of 146 drugs, including expensive patented ones like Keytruda, remain unchanged, exposing policy gaps.
2Facts to remember
Tap a card to see the answer. Try to recall it first.
3Detailed analysis
Context / Background
This regulatory action stems from longstanding public and judicial concern over exorbitant cancer drug prices in India. The Supreme Court, in September 2026, termed high cancer drug prices a 'massacre' and questioned the government on the wide gap between procurement cost and MRP. The NPPA operates under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, and regulates drug prices under the Drugs (Prices Control) Order (DPCO).
Core Analysis & Implications
The price revision demonstrates the impact of the Trade Margin Rationalization (TMR) policy, which aims to curb profiteering in the supply chain. The most drastic reduction is seen in Thiotepa 100mg injection (Samtepa), falling from Rs 80,071.86 to Rs 7,150.33. However, the policy's limitations are stark: patented drugs (e.g., Keytruda, Ribociclib) remain unaffected due to patent protections and complex supply chains. The policy also excludes drugs given free under patient assistance programs, missing an opportunity for broader price rationalization.
Future Outlook / Way Forward
The immediate challenge is ensuring the availability of reduced-price drugs and preventing companies from stopping supply. Long-term solutions require addressing policy flaws in TMR, such as the high permissible margin (up to 42.8%) on price-to-stockist for expensive drugs. Strengthening NPPA's data capabilities on supply chain pricing and exploring mechanisms like compulsory licensing or price negotiations for patented drugs are critical steps forward, as highlighted by the Supreme Court's intervention.
4Background GK
Textbook concepts you need to understand this news
- National Pharmaceutical Pricing Authority (NPPA)
- An independent body under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, responsible for controlling and revising the prices of scheduled and non-scheduled drugs in India under the Drugs (Prices Control) Order (DPCO).
- Drugs (Prices Control) Order (DPCO)
- An order issued by the Government of India under the Essential Commodities Act, 1955, to regulate the prices of essential and life-saving medicines. The National List of Essential Medicines (NLEM) forms the basis for drugs under price control.
- Trade Margin Rationalization (TMR)
- A policy mechanism to cap the trade margin (the difference between the price to the retailer/stockist and the Maximum Retail Price) to prevent excessive profiteering in the pharmaceutical supply chain.
5How exams will ask this
- Data: 543 cancer drugs revised, 397 (73%) prices reduced, effective 9 Nov 2026.
- Nodal Body: National Pharmaceutical Pricing Authority (NPPA) under Dept. of Pharmaceuticals.
- Policy: Trade Margin Rationalization (TMR) policy capping margin at 30% of MRP.
Don't make this mistake!
They may ask about the percentage of drugs with reduced prices (73%) versus the number of drugs with price cuts greater than 50% (217). They may also swap 'patented drugs' with 'generic drugs' when discussing unchanged prices, or confuse DPCO with TMR.
Write these in mains answers
Affordable Healthcare, Drug Price Regulation, Supply Chain Transparency, Patents vs. Public Health
6Practice questions
Pick an answer, then read the explanation.
- Q1Hard
Consider the following statements regarding the recent revision of cancer drug prices:
- 1.The National Pharmaceutical Pricing Authority revised prices for 543 cancer drug brands/packs.
- 2.Prices of all patented cancer drugs, including Keytruda, were significantly reduced in this revision.
- 3.The revised prices are a result of a government order capping the trade margin for anti-cancer drugs at 30% of the Maximum Retail Price.
Which of the statements given above is/are correct?
Explanation: Statement 1 is correct as the article states NPPA revised prices for 543 drug brands/packs. Statement 2 is incorrect; the article specifically mentions that prices of patented drugs like Keytruda remained unchanged. Statement 3 is correct as the revision followed a government order capping trade margins at 30% of MRP.
- Q2Medium
According to the news, from what date are the newly revised prices of cancer drugs set to become effective?
Explanation: The article explicitly states that the new prices will come into effect from 9 November 2026. The other dates are distractors not mentioned in the content.
- Q3Medium
What is the primary objective behind the government's order to cap trade margins for anti-cancer drugs, as reflected in the recent price revision?
Explanation: The core objective of capping trade margins at 30% of MRP is to prevent excessive profiteering in the supply chain, thereby making essential cancer drugs more affordable for patients. This is evident from the Supreme Court's concern over the high cost of treatment and the article's focus on patient relief.
7All sources
Original29 October 2026 · Read story